Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | “Brazilian Pharma Market To Reach $50.6bn In 2019”, Predicts New Visiongain StudyBy: Visiongain 
vg Visiongain’s investigation gives multilevel revenue forecasting and discussions that planners, influencers and leaders need. That company is a business information publisher and consultancy in London, UK. It produces data and analysis to help companies understand markets and their potentials. Arshad Ahad, a healthcare industry analyst in visiongain, said: “The future looks promising for the Brazilian pharmaceutical market. That emerging national market is growing at a much faster rate than more mature markets such as the US and the EU5, and will continue to do so over the next ten years. “With a large ageing population, rise in chronic diseases, booming generics market and a government looking to increase access to medicines, the demand for pharmaceuticals in Brazil has never been higher. Combined with a growing middle class and a government eager to make technology transfer deals with multinational companies, Brazil’s medicines market offers many lucrative opportunities. “To harness those possibilities, pharma companies will need to traverse a landscape of high competition, governmental regulation, high drug taxes and a range of other complications. Nevertheless, the Brazilian pharmaceutical market offers significant rewards and is crucial to healthcare companies’ growth strategies in the face of stagnation in developed national markets.” Visiongain’s new analysis contains revenue forecasts to 2025 for the overall Brazilian pharmaceutical market, and predictions to 2025 for six main submarkets: Patented therapies – original brands of prescription pharmaceuticals, also with prediction of vaccine and biological drug (grouped) revenues Generic drugs (prescription generics), also with grouped prediction of biosimilar revenues OTC medicines – over-the-counter drugs. That work also gives revenue forecasts to 2025 for six therapy areas: Central nervous system (CNS) products Cardiovascular (CV) treatments Alimentary and metabolic disorders therapy Cancer treatments (oncology) Infectious diseases – anti-infective agents (vaccines and antibiotics) Therapies for other illnesses (grouped). That study also profiles leading companies selling medicines in Brazil – domestic and multinational corporations. It analyses their products, outlooks, M&A activity, R&D and strategies for competing in that country. That work explores activities of EMS, Eurofarma, União Química, Cristália, Aché and other domestic competitors. It also examines foreign participants, including Pfizer, Sanofi, Novartis, Merck, Takeda and Bayer. Those analyses discuss driving and restraining forces for that market, including regulations and the effects of healthcare payers. That work covers small molecule medicines and biological drugs (biologics), including biosimilars and vaccines. The investigation shows opinions and news, including an interview with BiocadBrazil Farmaceutica. The study concludes that Brazil holds high potential for improving access to medicines, with benefits to healthcare providers, patients and pharmaceutical companies. Brazilian Pharmaceutical Market Outlook 2015-2025 adds to visiongain’s reports on industries and markets in healthcare. Those studies analyse pharmaceuticals, medical devices, diagnostics and contract services, showing their technological, clinical and commercial prospects. For sample pages and further information concerning the visiongain report Brazilian Pharmaceutical Market Outlook 2015-2025 please visithttps://www.visiongain.com/ For an executive summary please contact: Email: Sara Peerun on sara.peerun@ Tel: +44 (0) 20 7336 6100 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail tosara.peerun@ About Visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
